Yvonne Bryson, M.D., an infectious disease researcher at UCLA, presented the case of an American woman who was cured of HIV after receiving a new transplant procedure that leverages donated umbilical cord blood.

A new variant of HIV was recently discovered in Europe that is more contagious and more deadly – the virus degrades the immune system into AIDS twice as fast as previous strains.

GSK

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.

ViiV Healthcare’s HIV treatment Cabenuva was approved by the U.S. Food and Drug Administration for use every two months, meaning patients only have to receive an injectable dose six times per year.

Leading South African scientists are set to investigate COVID-19 and HIV in tandem, amid mounting evidence that the collision of the two pandemics could be generating new coronavirus variants.

Merck

Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.

Gilead Sciences Inc. said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of the company’s HIV treatments over the last two years, endangering patients.

As 2022 unfolds, pharmaceutical companies were quick to implement price increases on hundreds of prescription medications. According to research company 46brooklyn, drug manufacturers raised prices on 460 different medicines in the first days of January.

Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.

The U.S. Food and Drug Administration placed a clinical hold on Gilead Sciences’ use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV and HIV pre-exposure prophylaxis (PrEP).